局部晚期胃癌患者RAD51表达与新辅助治疗反应及预后的关系

IF 2.8 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-08-30 DOI:10.1080/14737140.2025.2555468

Serhat Sekmek, Serhat Ozan, Fahriye Tugba Kos, Hayriye Tatli Dogan, Mehmet Akif Parlar, Didem Sener Dede

{"title":"局部晚期胃癌患者RAD51表达与新辅助治疗反应及预后的关系","authors":"Serhat Sekmek, Serhat Ozan, Fahriye Tugba Kos, Hayriye Tatli Dogan, Mehmet Akif Parlar, Didem Sener Dede","doi":"10.1080/14737140.2025.2555468","DOIUrl":null,"url":null,"abstract":"Background: We aimed to investigate the effect of RAD51 expression on pathological response and survival in gastric cancer patients receiving fluorouracil plus leucovorin, cisplatin and docataxel (FLOT) as neoadjuvant chemotherapy (NACT).Research design and methods: RAD51 immunohistochemistry staining was performed in the endoscopy biopsies of the patients, and the pathological responses in the surgery of the patients after NACT were evaluated using the Ryan tumor regression score (RTRS).Results: 89 patients participated in this study. The factors affecting the pathological responses of the patients after NACT were examined, patients with high RAD51 nuclear expression percentage (NEP) responded better to NACT (p = 0.020). RAD51 nuclear expression density (NED) (p = 0.127), age (p = 0.999), sex (p = 0.098), clinical stage (p = 0.540), tumor pathology (p = 0.999) did not affect the pathological response after NACT. Age, gender, clinical stage, tumor pathology, RAD51 NEP or RAD51 NED did not affect DFS or OS. Patients with low RTRS had better DFS (p = 0.001) and OS (p = 0.009) results.Conclusions: As a result of our study, it was observed that patients with high RAD51 NEP had better pathological responses after NACT.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association of RAD51 expression with response to neoadjuvant treatment and prognosis in locally advanced gastric cancer.\",\"authors\":\"Serhat Sekmek, Serhat Ozan, Fahriye Tugba Kos, Hayriye Tatli Dogan, Mehmet Akif Parlar, Didem Sener Dede\",\"doi\":\"10.1080/14737140.2025.2555468\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: We aimed to investigate the effect of RAD51 expression on pathological response and survival in gastric cancer patients receiving fluorouracil plus leucovorin, cisplatin and docataxel (FLOT) as neoadjuvant chemotherapy (NACT).Research design and methods: RAD51 immunohistochemistry staining was performed in the endoscopy biopsies of the patients, and the pathological responses in the surgery of the patients after NACT were evaluated using the Ryan tumor regression score (RTRS).Results: 89 patients participated in this study. The factors affecting the pathological responses of the patients after NACT were examined, patients with high RAD51 nuclear expression percentage (NEP) responded better to NACT (p = 0.020). RAD51 nuclear expression density (NED) (p = 0.127), age (p = 0.999), sex (p = 0.098), clinical stage (p = 0.540), tumor pathology (p = 0.999) did not affect the pathological response after NACT. Age, gender, clinical stage, tumor pathology, RAD51 NEP or RAD51 NED did not affect DFS or OS. Patients with low RTRS had better DFS (p = 0.001) and OS (p = 0.009) results.Conclusions: As a result of our study, it was observed that patients with high RAD51 NEP had better pathological responses after NACT.\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2025.2555468\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2555468","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：我们旨在探讨RAD51表达对接受氟尿嘧啶联合亚叶酸素、顺铂和多卡他赛（FLOT）新辅助化疗（NACT）的胃癌患者病理反应和生存的影响。研究设计与方法：患者内镜活检行RAD51免疫组化染色，采用Ryan肿瘤回归评分（Ryan tumor regression score， RTRS）评价NACT术后患者手术病理反应。结果：89例患者参与本研究。检测影响NACT后患者病理反应的因素，RAD51核表达率（NEP）高的患者对NACT的反应更好（p = 0.020）。RAD51核表达密度（NED）（p = 0.127）、年龄（p = 0.999）、性别（p = 0.098）、临床分期（p = 0.540）、肿瘤病理（p = 0.999）对NACT术后病理反应无影响。年龄、性别、临床分期、肿瘤病理、RAD51 NEP或RAD51 NED对DFS和OS均无影响。低RTRS患者有更好的DFS （p = 0.001）和OS （p = 0.009）结果。结论：我们的研究发现，高RAD51 NEP的患者在NACT后有更好的病理反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Association of RAD51 expression with response to neoadjuvant treatment and prognosis in locally advanced gastric cancer.

Background: We aimed to investigate the effect of RAD51 expression on pathological response and survival in gastric cancer patients receiving fluorouracil plus leucovorin, cisplatin and docataxel (FLOT) as neoadjuvant chemotherapy (NACT).

Research design and methods: RAD51 immunohistochemistry staining was performed in the endoscopy biopsies of the patients, and the pathological responses in the surgery of the patients after NACT were evaluated using the Ryan tumor regression score (RTRS).

Results: 89 patients participated in this study. The factors affecting the pathological responses of the patients after NACT were examined, patients with high RAD51 nuclear expression percentage (NEP) responded better to NACT (p = 0.020). RAD51 nuclear expression density (NED) (p = 0.127), age (p = 0.999), sex (p = 0.098), clinical stage (p = 0.540), tumor pathology (p = 0.999) did not affect the pathological response after NACT. Age, gender, clinical stage, tumor pathology, RAD51 NEP or RAD51 NED did not affect DFS or OS. Patients with low RTRS had better DFS (p = 0.001) and OS (p = 0.009) results.

Conclusions: As a result of our study, it was observed that patients with high RAD51 NEP had better pathological responses after NACT.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.